Incorporating albumin-bilirubin grade and up-to-seven criteria to predict outcomes of patients with intermediate stage hepatocellular carcinoma after transarterial (chemo)embolization
Background/Purpose: This study is to use albumin-bilirubin (ALBI) grade and up-to-7 (UT7) criteria to assess outcomes of patients with intermediate stage hepatocellular carcinoma (HCC) after transarterial (chemo)embolization (TA(C)E). Methods: Between January 2012 and January 2019, newly diagnosed i...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-04-01
|
| Series: | Journal of the Formosan Medical Association |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0929664621003156 |
| _version_ | 1818776523101962240 |
|---|---|
| author | Hsin-Yeh Chen Kwong-Ming Kee Sheng-Nan Lu Jing-Houng Wang Chien-Hung Chen Chao-Hung Hung Yi-Hao Yen Yuan-Hung Kuo |
| author_facet | Hsin-Yeh Chen Kwong-Ming Kee Sheng-Nan Lu Jing-Houng Wang Chien-Hung Chen Chao-Hung Hung Yi-Hao Yen Yuan-Hung Kuo |
| author_sort | Hsin-Yeh Chen |
| collection | DOAJ |
| description | Background/Purpose: This study is to use albumin-bilirubin (ALBI) grade and up-to-7 (UT7) criteria to assess outcomes of patients with intermediate stage hepatocellular carcinoma (HCC) after transarterial (chemo)embolization (TA(C)E). Methods: Between January 2012 and January 2019, newly diagnosed intermediate HCC patients underwent TA(C)E were enrolled and analyzed. The demographics, clinical characteristics and survival were obtained from medical chart reviews. Results: A total of 359 patients were enrolled and 30.4% of them were within UT7 criteria (UT7 (−)). There were 36.5%, 59.3%, and 4.2% of the patients with ALBI grade I, II, and III, respectively. Beyond UT7 (UT7 (+)) and ALBI grade II/III were associated with overall mortality in multivariate analysis. Based on ALBI grade I/II/III and UT7 −/+, patients were classified into six groups as ALBI grade I plus UT7 (−), II plus UT7 (−), III plus UT7 (−), I plus UT7 (+), II plus UT7 (+), and III plus UT7(+). Distributions of median survival were 47.5, 32.9, 15, 34.3, 16.7 and 14.3 months, respectively. Patients with statistically insignificant survivals were further combined. Patients with ALBI grade I plus UT7 (−) were reclassified as ALBI-U class I, whereas ALBI grade II plus UT7 (−) and I plus UT7 (+) were ALBI-U class II, and the others were ALBI-U class III. There were 8.4%, 48.7%, and 42.9% of patients in ALBI-U class I, II, and III, respectively. The 5-year survival rate was 48.8%, 22.5%, and 13.7% in ALBI-U class I, II, and III, respectively (p < 0.01). Conclusion: ALBI-U classification was useful in predicting outcomes of patient with intermediate stage HCC after TA(C)E. |
| first_indexed | 2024-12-18T11:14:17Z |
| format | Article |
| id | doaj.art-d5b5b3072c454caabf585f5f5407a86f |
| institution | Directory Open Access Journal |
| issn | 0929-6646 |
| language | English |
| last_indexed | 2024-12-18T11:14:17Z |
| publishDate | 2022-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of the Formosan Medical Association |
| spelling | doaj.art-d5b5b3072c454caabf585f5f5407a86f2022-12-21T21:09:58ZengElsevierJournal of the Formosan Medical Association0929-66462022-04-011214778786Incorporating albumin-bilirubin grade and up-to-seven criteria to predict outcomes of patients with intermediate stage hepatocellular carcinoma after transarterial (chemo)embolizationHsin-Yeh Chen0Kwong-Ming Kee1Sheng-Nan Lu2Jing-Houng Wang3Chien-Hung Chen4Chao-Hung Hung5Yi-Hao Yen6Yuan-Hung Kuo7Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung City, TaiwanDivision of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung City, TaiwanDivision of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung City, TaiwanDivision of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung City, TaiwanDivision of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung City, TaiwanDivision of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung City, TaiwanDivision of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung City, TaiwanCorresponding author. Division of Hepatogastroenterology, Kaohsiung Chang Gung Memorial Hospital, 123 Ta-Pei Rd, Niao-Sung, 833, Kaohsiung City, Taiwan. Tel.: +886 7 7317123x8301; fax: +886 7 7322402.; Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung City, TaiwanBackground/Purpose: This study is to use albumin-bilirubin (ALBI) grade and up-to-7 (UT7) criteria to assess outcomes of patients with intermediate stage hepatocellular carcinoma (HCC) after transarterial (chemo)embolization (TA(C)E). Methods: Between January 2012 and January 2019, newly diagnosed intermediate HCC patients underwent TA(C)E were enrolled and analyzed. The demographics, clinical characteristics and survival were obtained from medical chart reviews. Results: A total of 359 patients were enrolled and 30.4% of them were within UT7 criteria (UT7 (−)). There were 36.5%, 59.3%, and 4.2% of the patients with ALBI grade I, II, and III, respectively. Beyond UT7 (UT7 (+)) and ALBI grade II/III were associated with overall mortality in multivariate analysis. Based on ALBI grade I/II/III and UT7 −/+, patients were classified into six groups as ALBI grade I plus UT7 (−), II plus UT7 (−), III plus UT7 (−), I plus UT7 (+), II plus UT7 (+), and III plus UT7(+). Distributions of median survival were 47.5, 32.9, 15, 34.3, 16.7 and 14.3 months, respectively. Patients with statistically insignificant survivals were further combined. Patients with ALBI grade I plus UT7 (−) were reclassified as ALBI-U class I, whereas ALBI grade II plus UT7 (−) and I plus UT7 (+) were ALBI-U class II, and the others were ALBI-U class III. There were 8.4%, 48.7%, and 42.9% of patients in ALBI-U class I, II, and III, respectively. The 5-year survival rate was 48.8%, 22.5%, and 13.7% in ALBI-U class I, II, and III, respectively (p < 0.01). Conclusion: ALBI-U classification was useful in predicting outcomes of patient with intermediate stage HCC after TA(C)E.http://www.sciencedirect.com/science/article/pii/S0929664621003156Albumin-bilirubin gradeHepatocellular carcinomaIntermediate stageTransarterial embolizationUp-to-7 |
| spellingShingle | Hsin-Yeh Chen Kwong-Ming Kee Sheng-Nan Lu Jing-Houng Wang Chien-Hung Chen Chao-Hung Hung Yi-Hao Yen Yuan-Hung Kuo Incorporating albumin-bilirubin grade and up-to-seven criteria to predict outcomes of patients with intermediate stage hepatocellular carcinoma after transarterial (chemo)embolization Journal of the Formosan Medical Association Albumin-bilirubin grade Hepatocellular carcinoma Intermediate stage Transarterial embolization Up-to-7 |
| title | Incorporating albumin-bilirubin grade and up-to-seven criteria to predict outcomes of patients with intermediate stage hepatocellular carcinoma after transarterial (chemo)embolization |
| title_full | Incorporating albumin-bilirubin grade and up-to-seven criteria to predict outcomes of patients with intermediate stage hepatocellular carcinoma after transarterial (chemo)embolization |
| title_fullStr | Incorporating albumin-bilirubin grade and up-to-seven criteria to predict outcomes of patients with intermediate stage hepatocellular carcinoma after transarterial (chemo)embolization |
| title_full_unstemmed | Incorporating albumin-bilirubin grade and up-to-seven criteria to predict outcomes of patients with intermediate stage hepatocellular carcinoma after transarterial (chemo)embolization |
| title_short | Incorporating albumin-bilirubin grade and up-to-seven criteria to predict outcomes of patients with intermediate stage hepatocellular carcinoma after transarterial (chemo)embolization |
| title_sort | incorporating albumin bilirubin grade and up to seven criteria to predict outcomes of patients with intermediate stage hepatocellular carcinoma after transarterial chemo embolization |
| topic | Albumin-bilirubin grade Hepatocellular carcinoma Intermediate stage Transarterial embolization Up-to-7 |
| url | http://www.sciencedirect.com/science/article/pii/S0929664621003156 |
| work_keys_str_mv | AT hsinyehchen incorporatingalbuminbilirubingradeanduptosevencriteriatopredictoutcomesofpatientswithintermediatestagehepatocellularcarcinomaaftertransarterialchemoembolization AT kwongmingkee incorporatingalbuminbilirubingradeanduptosevencriteriatopredictoutcomesofpatientswithintermediatestagehepatocellularcarcinomaaftertransarterialchemoembolization AT shengnanlu incorporatingalbuminbilirubingradeanduptosevencriteriatopredictoutcomesofpatientswithintermediatestagehepatocellularcarcinomaaftertransarterialchemoembolization AT jinghoungwang incorporatingalbuminbilirubingradeanduptosevencriteriatopredictoutcomesofpatientswithintermediatestagehepatocellularcarcinomaaftertransarterialchemoembolization AT chienhungchen incorporatingalbuminbilirubingradeanduptosevencriteriatopredictoutcomesofpatientswithintermediatestagehepatocellularcarcinomaaftertransarterialchemoembolization AT chaohunghung incorporatingalbuminbilirubingradeanduptosevencriteriatopredictoutcomesofpatientswithintermediatestagehepatocellularcarcinomaaftertransarterialchemoembolization AT yihaoyen incorporatingalbuminbilirubingradeanduptosevencriteriatopredictoutcomesofpatientswithintermediatestagehepatocellularcarcinomaaftertransarterialchemoembolization AT yuanhungkuo incorporatingalbuminbilirubingradeanduptosevencriteriatopredictoutcomesofpatientswithintermediatestagehepatocellularcarcinomaaftertransarterialchemoembolization |